BioCryst Pharmaceuticals Updated Its Agreement With Torii Pharmaceutica For ORLADEYO In Japan; BioCryst Japan K.K. Responsible For All Commercial Promotion Activities And Torii Will Be Responsible For Hereditary Angioedema Disease Awareness Activities
Portfolio Pulse from Benzinga Newsdesk
BioCryst Pharmaceuticals has revised its agreement with Torii Pharmaceutical regarding ORLADEYO in Japan. BioCryst Japan K.K. will now handle all commercial promotion, while Torii focuses on hereditary angioedema disease awareness activities, according to an SEC filing.
November 30, 2023 | 2:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioCryst Pharmaceuticals has modified its partnership terms with Torii Pharmaceutical for the promotion of ORLADEYO in Japan, potentially affecting its market reach and sales in the region.
The updated agreement could lead to more focused and effective commercial promotion efforts by BioCryst Japan K.K., which may increase ORLADEYO's market penetration and sales in Japan. Torii's role in raising disease awareness could also indirectly support the drug's market position by increasing the potential patient base.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80